A phase 1 randomized study of Tarceva (erlotinib) in patients with stage IIIB/IV non-small cell lung cancer after failure of one or two prior chemotherapy regimens and who currently smoke.

Trial Profile

A phase 1 randomized study of Tarceva (erlotinib) in patients with stage IIIB/IV non-small cell lung cancer after failure of one or two prior chemotherapy regimens and who currently smoke.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors OSI Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Planned end date changed from 1 Jul 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Results were published in the JCO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top